Company intelligence / Profile preview

Distributed Bio

San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

Distributed Bio developed platform technologies for antibody and vaccine discovery, generating high-affinity antibodies and universal vaccine candidates. The company contributed COVID-19 antibody engineering and universal vaccine projects. Most programs were at the discovery and pre-clinical stage prior to acquisition.

Therapeutic areas: OncologyNeurologyInfectious Diseases
Modalities: Monoclonal antibodyAntibodyPeptideTCR (T cell receptor)
Industry: Biotech

Partnerships

Many undisclosed pharma/biotech partners for antibody programsCarterra (Collaboration on rapid antibody screening)

Beyond the preview

Go deeper on Distributed Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Distributed Bio.

Explore the full profile